Le Profil Pays constitue donc un document de référence pour tout chercheur, praticien et acteur intéressé par la planification familiale en général et par les besoins non satisfaits en particulier. Il fournit de précieux éclairages pour le renforcement des programmes actuels et futurs et la ...réduction des grossesses non désirées au Sénégal.
more
This Guide helps all the health care providers in the non- public sector to explore alternative means of access to contraceptives and skills to determine quantities required and management of stock. Health care providers include community health workers, nurses and midwives, clinical officers and me...dical doctors.
more
This progress report reflects achievements made during the first year of implementation (through December 2016), as countries have taken actions in line with new or existing national strategies. The most recent data on country progress in 2016 are based on country-reported data and country-developed... models using Spectrum software that were reported to UNAIDS in 2017.
more
Further Analysis of the 2000, 2005, and 2011 Demographic and Health Surveys. DHS Further Analysis Reports No. 81
DHS Working Papers No. 104.
The coronavirus disease 2019 (COVID-19) pandemic has created a global and gendered crisis that is compounding existing inequalities and disproportionately affecting girls and women. Emerging evidence from the COVID-19 crisis in 2020 shows school closures, disruptions in essential services and rising... poverty contributed to girls’ increased risk of female genital mutilation (FGM). School closures limited the monitoring and reporting of cases of FGM. Rising household monetary poverty may have contributed to families adopting negative coping mechanisms, including having girls undergo FGM as a precursor to marriage to reduce household costs. A report from the United Nations Population Fund (UNFPA) estimates 2 million additional cases of FGM by 2030 due to the pandemic.
more
Developing protocols for use with refugees
and internally displaced persons
Journal of Virus Eradication 2018; 4 (Supplement 2): 33–39
Bishkek 2015
Accessed: 26.09.2019
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more